PELOSI, NANCY BUYNVDA$500K–$1M·TUBERVILLE, TOMMY BUYMSFT$50K–$100K·CRENSHAW, DAN SELLXOM$15K–$50K·PELOSI, NANCY BUYNVDA$500K–$1M·TUBERVILLE, TOMMY BUYMSFT$50K–$100K·CRENSHAW, DAN SELLXOM$15K–$50K·
K-STREET TRACKER

FOLLOW THE MONEY INTO THE SWAMP

Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.

Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies

💸 Top Spending Clients

🎯 Top Lobbied Tickers

#TickerFilingsTotal $
1META
Meta Platforms Inc.
129$50.2M
2PFE
Pfizer Inc.
87$48.6M
3GM
General Motors Company
103$48.4M
4V
Visa Inc.
46$37.7M
5AMZN
Amazon.com Inc.
80$35.3M
6LMT
Lockheed Martin Corporation
88$29.4M
7FDX
FedEx Corporation
82$28.3M
8LLY
Eli Lilly and Company
83$28.1M
9AMGN
Amgen Inc.
95$28.0M
10MRK
Merck & Co. Inc.
92$27.5M
11AAPL
Apple Inc.
64$26.8M
12GOOGL
Alphabet Inc. Class A
123$26.6M
13MO164$26.2M
14SO
Southern Company
108$26.1M
15UNH
UnitedHealth Group Inc.
67$23.9M
16VZ
Verizon Communications Inc.
116$23.8M
17TMUS159$22.7M
18CHTR137$22.6M
19GD
General Dynamics Corporation
127$22.5M
20T
AT&T Inc.
134$21.6M
21ORCL
Oracle Corporation
132$20.6M
22CMCSA
Comcast Corporation
141$20.4M
23CI
The Cigna Group
64$19.9M
24OXY
Occidental Petroleum Corporation
36$19.9M
25MSFT
Microsoft Corporation
122$19.2M

🆕 Filtered Filings · MODERNATX INC.

clear filters
DateTickerClientRegistrantAmountIssue
2026-04-20MRNAMODERNATX INC.STANTON PARK GROUP$50KIssues related to COVID 19 vaccines, mRNA drug discovery, drug development and related issues.
2026-04-01MRNAMODERNATX INC.THE WASHINGTON TAX & PUBLIC POLICY GROUP$30KIssues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 41, 45C, 951A, 250, and 174. (H.R. 1414).
2026-01-20MRNAMODERNATX INC.STANTON PARK GROUP$50KIssues related to COVID 19 vaccines, mRNA drug discovery, drug development and related issues.
2026-01-16MRNAMODERNATX INC.THE WASHINGTON TAX & PUBLIC POLICY GROUP (FORMERLY THE WASHINGTON TAX GROUP)$30KIssues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 45C, 951A, 250, and 174. (H.R. 1990, S. 1639, H.R. 1062, H.R. 1414, H.R. 1 - Sections 70231, 70322, 70323, 70302).
2025-10-20MRNAMODERNATX INC.STANTON PARK GROUP$50KIssues related to COVID 19 vaccines, mRNA drug discovery, drug development and related issues.
2025-10-13MRNAMODERNATX INC.THE WASHINGTON TAX & PUBLIC POLICY GROUP (FORMERLY THE WASHINGTON TAX GROUP)$30KIssues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, 164(a), and 174. (H.R. 1990, S. 1639, H.R. 1062, H.R. 1 - Sections 70231, 70322, 70323, 70302).
2025-07-21MRNAMODERNATX INC.STANTON PARK GROUP$50KIssues related to COVID 19 vaccines, mRNA drug discovery, drug development and related issues.
2025-07-10MRNAMODERNATX INC.THE WASHINGTON TAX & PUBLIC POLICY GROUP (FORMERLY THE WASHINGTON TAX GROUP)$30KIssues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, 164(a), and 174. (H.R. 1990, S. 1639, H.R. 1062, H.R. 1 - Sections 70231, 70322, 70323, 70302).
2025-04-21MRNAMODERNATX INC.STANTON PARK GROUP$50KIssues related to COVID 19 vaccines, mRNA drug discovery, drug development and related issues.
2025-04-17MRNAMODERNATX INC.THE WASHINGTON TAX & PUBLIC POLICY GROUP (FORMERLY THE WASHINGTON TAX GROUP)$30KIssues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, 174 and 41. (H.R. 1990, H.R. 1062).
2025-01-21MRNAMODERNATX INC.BROWNSTEIN HYATT FARBER SCHRECK, LLP$80KIssues related to drug discovery, drug development, vaccine technologies, and coverage and reimbursement Issues related to biotechnology legislation and supply chain Issues related to international vaccine deployment
2025-01-21MRNAMODERNATX INC.STANTON PARK GROUP$50KIssues related to COVID 19 vaccines, mRNA drug discovery, drug development and related issues.